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Despite the fact that there have been many reports on benzodiazepine 
(BZD) dependence, consensus about its definition has not been reached. 
Reliable prevalence data to estimate the dependence liability of BZDs are 
therefore lacking. This study is the first to assess the prevalence of BZD 
dependence in out-patient BZD users (115 general practice (GP) patients, 
124 psychiatric out-patients and 33 self-help patients) on the basis of the 
DSM-III-R and ICD-10 substance dependence criteria. Past year and 
lifetime diagnoses of BZD dependence were made by means of the 
Schedules for Clinical Assessments in Neuropsychiatry (SCAN). High 
prevalence figures were found, ranging from 40% in the GP patients 
(DSM-III-R past year) to 97% in the self-help patients (ICD-10 lifetime), 
indicating that BZD users run a high risk of developing BZD dependence, 
The clinical management of BZD use could benefit from further 
development of diagnostic instruments such as a self-report questionnaire 
which reflects the severity of BZD dependence*
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Introduction
Since the benzodiazepines (BZDs) were intro­
duced in the early 1960s, the number of reports on 
their liability to cause dependence has been 
increasing steadily. The earliest reports in which the 
term BZD dependence was used were concerned 
with withdrawal reactions after the abrupt cessation 
of high doses of BZDs (1, 2).
In 1964, the World Health Organization (WHO) 
expert committee on dependence-producing drugs
(3) adopted the term dependence in a broader 
sense by replacing the confusing former terms 
‘addiction’ and ‘habituation’ with definitions of 
physical and psychological dependence. Neverthe­
less, in many reports the term ‘BZD dependence’ 
continued to be used for the physical phenomena 
of tolerance and withdrawal, while the term ‘addic­
tion’ was still used to refer to psychological aspects 
of dependence, such as ‘compulsion to use’, ‘loss 
of control’, ‘continued use despite adverse conse­
quences’ and ‘drug-seeking behaviour’ (4, 5).
Since 1981, the WHO has been propagating a 
psycho-physiological-social model for dependence
called the ‘drug dependence syndrome’ (6). This 
syndrome acquired enough support in studies in 
which it was applied to alcohol and other sub­
stances (7, 8) for it to become the primary source 
of the general substance dependence criteria of 
the Diagnostic and Statistical Manual of Mental 
Disorders-IlI-Revised (DSM-III-R) (9) and the 
International Classification of Diseases, JOlh edition
(ICD-10) (10).
In a recent literature review on the definition of 
BZD dependence, Linsen et al. (11) found that 
DSM and ICD substance dependence criteria had 
been used in only a small number of the 250 papers 
reviewed. Definitions of BZD dependence which 
emphasized the physical aspects were still predomi­
nant. It was concluded that consensus about the 
definition of BZD dependence had not yet been 
reached, and that this limited the scope for assess­
ing the prevalence of BZD dependence. We con-
this view by a search in the medical 
literature for reports in which the prevalence of 
BZD dependence was assessed, which yielded the
1* 4
on psychoactive substances, including the BZDs, limited number of reports shown in Table 1 (12-20).
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Table 1. Studies published an the prevalence of BZD dependence
Study Sampie Definition of BZD dependence Method/instrument Results
Halístrom et al. 1982 (12) 58 long-term BZD users 
{Phobics Society!
(a) two or more withdrawal symptoms
(b) withdrawal symptoms emerging 
and subsiding spontaneously
Tranquillizer Usage
Survey
{a) 26% (14/58) 
(b) 5% (3/58)
Leux & König 1985 (13) 33 DOO admissions in 
psychiatric registers
No definition given Retrospective register 
study
0.5% (150/33000)
Fleischhacker et al. 1986 (14) (i) 10861 psychiatric in- and 
out-patients {BZD and 
non-BZD users)
(ii) estimated BZD-using psychiatric 
in-patients: 70%
(i)laî WHÛ/ICD-9 criteria 
(b) WH0/1CD-9 and DSM-lli criteria
{îl} WHO/ÎCD-9 criteria
(i) retrospective chart 
study
{ii) estimation
(i) in-patients/out-patients:
(a) 1.3% (9/5304)/1.7% (94/5557)
(b) 0.2% (9/5304}/0.4% (21/bbb/) 
(ii} in-patients, 1.8%
Schmidt et al. 1989 (15) 15 296 psychiatric inpatients DSM-ili criteria Drug surveillance 
system and case 
conferences
4.7% {726/15296) BZD 
dependence orabuse
Prisbe et aí. 1989 {16} 134 BZD-positive (tested in urine) 
psychiatric in-patients 
out of a sample of 899 
psychiatric in-patients
I CD-9 criteria Thorough psychiatric 
examination
4% (6/134) BZD dependence
Wolf et al. 1989 (17) Psychiatric in-patients WHO criteria {equivalent to ICD-9) Structured question­
naire, case conference
5.6% (633 patients) BZD
dependence or abuse
Anthony & Heizer 1991 (18) Epidemiologic Catchment Anea (EGA) 
Surveys of residents aged 18 years 
and older between 1980 and 1984
DSM-HI criteria for lifetime dependence 
on and abuse of barbiturates, 
sedatives or hypnotics
Diagnostic interview
Schedule {DIS}
1.2% non-prescription use 
and abuse/dependence 
in total surveyed population
Hess, 1993 (19) 443 patients with DSM-lll 
alcohol dependence or abuse
DSM-IÜ criteria for lifetime dependence
on barbiturates, 
sedatives or hypnotics
DIS, 3rd version 18% dependence
{of which 8% was also abuse}
Anthony et 2!. 1994 (20) National Comorbidity Survey (NCS) 
of US household residents 
15 to 54 years of age between 1990 and 
1992
DSM-IÜ-R criteria for lifetime 
dependence on and abuse of 
barbiturates, sedatives or hypnotics
Composite
International
Diagnostic
interview
{CIDI)
1.2% in total surveyed population;
9.2% dependence in non-medical users 
of barbiturates, sedatives or hypnotics
Prevalence of benzodiazepine dependence
The prevalence data on BZD dependence would based on the DSM-III-R and ICD-10 substance 
be of most value if they could be based on uni- dependence criteria. In the light of the results 
formly accepted general criteria. The DSM-III-R obtained, the management of BZD use in clinical 
and ICD-10 classifications have gained worldwide practice is discussed, 
recognition, and their substance dependence criteria 
have been employed with promising results in 
addiction research concerning a number of dif­
ferent substances (7, 8). From the premises of the 
WHO that the drug dependence syndrome is a 
uniform construct for all substances, including 
BZDs, it follows that the DSM-III-R and ICD-10
substance dependence criteria should be used to 
assess the prevalence of BZD dependence. In fact, 
we found that in most of the studies listed in Table
1 (14-19), the DSM-III (21) and/or the ICD-9 (22) 
versions were used, while the DSM-III-R had only 
been applied in the National Comorbidity Survey 
(NCS) to date (20). As the concept of the drug 
dependence syndrome was introduced in the DSM- 
III-R and the ICD-10, it was only taken into 
account in the NCS. Unfortunately, in the NCS 
as well as in the Epidemiologic Catchment Area 
(ECA) Survey (18) and the study of Ross et al.
(19), no distinction was made between the BZDs 
and the other anxiolytics, sedatives and hypnotics. 
This unnecessary masking of the BZDs is probably 
due to the fact that this distinction is not standard­
ized in the structured diagnostic interviews which 
were used. We recommend the use of such instru­
ments, because this improves diagnostic reliability, 
but if meaningful prevalence data on the BZDs 
are required, a distinction should be made between 
the BZDs and the other sedatives, anxiolytics and 
hypnotics. Another distinction, namely that bet­
ween BZD dependence and abuse, was not made 
in the studies of Schmidt et al. and Wolf et al. (15, 
17), which made it impossible to interpret their 
prevalence results in terms of dependence alone.
As BZD use is a conditio sine qua non for 
BZD dependence, the prevalence in patients who
Material and methods
Settings and subjects
This study was conducted at four general practices, 
three psychiatric out-patient departments and two 
self-help groups concerned with the use of addic­
tive medication. The general practices were located 
in Nijmegen or nearby, while the psychiatric out­
patient departments were located in Nijmegen, 
Eindhoven and Apeldoorn. The self-help groups 
‘Stichting Vrouwen en Medicijngebruik’ (Women 
and Medication Use Foundation) and 'Stichting 
Phoenix’ (Phoenix Foundation) are active at vari­
ous locations in The Netherlands.
To be eligible to participate in the investigation, 
the subjects had to fulfil the following inclusion 
criteria: (i) actual BZD use; (ii) average frequency 
of BZD use of at least once a week; (iii) age 
between 17 and 70 years; (iv) ability to speak and 
read Dutch.
The patients who visited the general practices, 
psychiatric out-patient departments or self-help 
group meetings during the study period, or who 
had an individual contact with a self-help team 
member, were screened according to these inclu­
sion criteria. Eligible patients were asked to 
participate by a representative of the treatment or 
self-help team. Informed consent was obtained 
from the majority of the selected subjects, i.e. 67% 
(115 of 172) of the general practice (GP) patients, 
70% (124 of 178) of the psychiatric out-patients 
and 70% (33 of 47) of the self-help patients. 
The total sample of participants consisted of 272 
subjects. In addition, 16% (27 of 172) of the
use BZDs most clearly reflects the risk of BZD GP patients and 18% (32 of 178) of the eligible 
dependence. In the ECA Survey (18) and the NCS psychiatric out-patients who did not participate in
(20), the prevalence of dependence was assessed the entire study were prepared to provide their 
in the subpopulations of non-medical BZD users 
only, which excluded the medical users. Only 
Fleischhacker et al. (14) recognized that all BZD
sociodemographic data on request. No significant 
differences were found in the sociodemographic 
data (%2 and r-tests; P>0.05) between the above­
users should be considered as a separate subgroup. mentioned non-participants and the participants, 
They estimated a BZD dependence rate of 1.8% which argues in favour of the representativeness of
in their psychiatric in-patients who were using 
BZDs, on the basis of the ICD-9 criteria and a 
figure of 70% BZD use in their in-patients on one 
particular day.
To obtain more reliable data which would pro-
the data for the participating GP patients and 
psychiatric out-patients.
Study design
vide more insight into the liability of BZDs to cause This study forms part of a larger project being
dependence, we decided to assess the prevalence 
of BZD dependence in three groups of out-patient
conducted by the University of Nijmegen Research 
Group on Addictive Behaviours (UNRAB) in 
BZD users using a structured diagnostic instrument The Netherlands on the diagnosis and detection
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of BZD dependence. The study population of BZD use and the degree of psychopathology are
participated in two interviews, separated by an shown in Table 2.
interval of 3 weeks. During the first interview, In all three groups female subjects outnumbered
sociodemographic data were collected, followed male subjects. However, it should be pointed out
by the administration of the Benzodiazepine that the very high female: male ratio (85:15) in the
Dependence-Self Report Questionnaire (Bendep- self-help sample is partly due to the fact that
SRQ), the L-scale of the Minnesota Multiphasic membership of one of the self-help groups was
Personality Inventory (MMPI-2), the Benzodiaze- restricted to women. The mean age ranged from 44
pine Dependence-Structured Diagnostic Interview 
(Bendep-SDI) and the Schedules for Clinical 
Assessments in Neuropsychiatry (SCAN) (23). The 
Bendep-SRQ and Bendep-SDI have been con-
years in the self-help patients to 50 years in the GP 
patients. All of the subjects were of Dutch nation­
ality, and the majority (96-98%) also had a Dutch 
cultural background. In all three groups most out-
structed by our own research group. The second patients were married or in a steady relationship,
interview, which was conducted by the same inter- Our samples showed different profiles with regard
viewer as the first, consisted of the repeated to living arrangements, level of education and
administration of the Bendep-SRQ, followed by financial income. It appeared that most GP patients
the Symptom Checklist-90 (SCL-90) (24) and the were living without a partner and supporting tliem-
Addiction Severity Index-Revised (ASI-R). This selves financially, while most self-help patients
report focuses mainly on the results of the SCAN. were living with a partner and were supported 
by their partner’s income. Most of the psychiatric
The Schedules for Clinical Assessments in Neuropsychiatry (SCAN)
The SCAN, in which both the DSM-III-R and ICD- 
10 criteria are operationalized in a semi-structured 
format, were developed in the WHO/US National 
Institutes of Health (NIH) Joint Project on Diag­
nosis and Classification of Mental Disorders and 
Alcohol- and Drug-Related Problems (25). In this 
study, we administered the sections ‘Alcohol’ and 
‘Use of psychoactive substances other than alcohol’ 
from the SCAN in the official Dutch translation 
(23), while reserving the category ‘sedatives’ for 
BZDs only. The DSM-III-R and ICD-10 past year 
(PY) and lifetime (LT) diagnoses of BZD depen­
dence were calculated using the algorithms that 
are also being used in the WHO/NIH Reliability 
and Validity Study on Alcohol and Drugs, an 
international multicentre trial which is currently in 
progress at the Amsterdam Institute for Addiction 
Research and other centres.
Statistical analysis
out-patients were living with a partner and were 
supporting themselves.
To reflect the mean BZD dose used daily of all 
the different BZDs by one parameter, we calcu­
lated the ‘mean daily BZD close/defined daily BZD 
dose ratio (MDD/DDD)’, where the ‘DDD ’ is the 
defined daily dose recommended by the WHO. If 
more than one BZD was used, the mean of the 
separate MDD/DDD values was used. On average, 
the GP patients used the lowest BZD dose, even 
lower than the recommended therapeutic level, 
shown by a MDD/DDD ratio of 0.9. The present 
duration of use of BZDs was expressed as the 
number of months as recalled by the patient. Only 
short durations (less than 2 months) were expressed 
in weeks. If more than one BZD was used, the 
duration of the BZD first prescribed was used to 
obtain the mean duration of BZD use, which is 
ill own in Table 2.
In all of the groups the mean duration of BZD 
use indicated long-term use. In the psychiatric out­
patients the average value of 40 months of BZD 
use was much lower than in the other two groups,
To determine whether the prevalence of BZD which might be due to the transfer of long-term 
dependence differed significantly between the three BZD prescription from psychiatrists to general 
out-patient groups, contrasts were tested pairwise 
by Chi-square analyses. Therefore, Bonferroni’s 
correction was applied, lowering the threshold for 
significance from P<0.05 to jp<0.017.
Results
Sociodemographic characteristics, pattern of BZD use and degree 
of psychopathology
The sociodemographic characteristics of our out­
patient samples, the BZD dose used, the duration psychopathology.
practitioners.
The highest degree of psychopathology, as 
reflected by the total score on the SCL-90, was 
observed not in the psychiatric out-patients but in 
the self-help patients. Of course, self-help for addic­
tive medication use does not exclude the possibility 
that these self-help patients might have been 
receiving psychiatric help as well. On the other 
hand, it is also possible that a number of these 
self-help patients did not find the professional help
, or as a result of, their
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Table 2. Sociodemographic characteristics of BZD users, BZD doso, duration of BZD use and SCL-90 total score''
Sociodemographic variables
General practice 
patients 
(n=115)
Psychiatric out-patients 
[a =124)
Self-help patients 
in = 33)
Sex (%)
Male 30 42 15
Female 70 58 85
Mean age±SD (years) 50 ±13 47 ±12 44 ±11
Marital/social status (%)
Single/never married 23 13 12
Engaged/in steady relationship 4 10 12
Married 48 55 58
Divorced 17 15 18
Widowed 10 7 0
Living arrangement (%)
Alone 49 29 27
With partner 40 61 67
Other 11 10 6
Level of education (%)
Primary 46 50 33
Secondary 23 31 49
Advanced 31 19 18
Financial income (%)
Profession 23 23 9
Unemployment benefit 15 10 18
Disability benefit 26 36 27
Pension 13 12 6
Partner's income 14 15 36
Other 10 3 3
MDD/DDD8 0.9 1.2 1.3
Quartiles 0.25-0.5-1.0 0.5-0 .9-1 .5 0.5-1.0-2.0
Mean duration of BZD use
(months) 88 40
Quartiles 9-48-120 6-13-42 20-90-152
SCL-90 mean total score
Psychoneuroticism±SD 169*±  63 177c ±62 223 ±69
a MDD/DDD, mean daily BZD dose/defined daily BZD dose. 
b n=  112, due to drop-outs after the first interview.
0 /?=120, due to drop-outs after the first interview. 
d Data are expressed as rounded-up figures.
The GP patients showed low prevalences of the 
criteria 'time involved in BZD-related activities’, 
'salience of BZD activities’ and also ‘tolerance’ if 
the cut-off point of the DSM-III-R was used. By
Diagnostic results
The group results after applying the DSM-III-R 
and ICD-10 criteria are shown in Tables 3 and 4.
These values were derived from the same responses comparison, the prevalence data for almost all of the 
on the same SCAN items, with the exception of criteria in the psychiatric out-patients were higher, 
‘social harm or repeated risk-taking behaviour’ and the self-help patients showed the highest prev- 
(only a DSM-III-R criterion) and ‘craving’ (only an alence values for all of the dependence criteria.
ICD-10 criterion). Furthermore, in contrast to the All of the observed prevalence values for PY and
DSM-III-R criteria, a number of ICD-10 criteria LT BZD dependence reflected by the DSM-III-R
are reflected by a combination of SCAN items, and and ICD-10 must be regarded as unexpectedly
the ICD-10 sets a lower cut-off point for‘tolerance’ high. The lowest PY prevalence of BZD depen-
than the DSM-III-R. These systematic differences dence was found in the GP patients, and it still
resulted in a higher prevalence of all ICD-10 amounted to 40% (for DSM-III-R) and 52% (for
diagnoses than DSM-III-R diagnoses. ICD-10). All of the LT prevalences were higher than
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Table 3, Past year (PY) and lifetime (LT) prevalence of positive DSM-III-R substanco dependence criteria and the diagnosis benzodiazepine (BZD) dependence0
General practice 
patients 
(/)= 115)
Psychiatric
out-patients
124)
Self-help 
patients 
{/?—33)
Dependence criteria PY LT PY LT PY LT
Impaired ability to control 
BZD use once started 14 26 14 15 36 67
Impaired ability to abstain from or 
reduce BZD use 59 67 70 77 79 94
Time involved in BZD-related 
activities 5 11 12 16 61 67
Social harm or repeated risk- 
taking behaviour 24 34 37 47 39 61
Salience of BZD activities U  24 35 36 49 67
Persistence in use despite 
harmful effects 12 17 27 27 42 58
Tolerance 9 17 13 17 27 58
Withdrawal symptoms 48 56 66 69 88 94
BZD use to relieve withdrawal 
symptoms 33 40 43 48 67 82
DSM-III-R diagnosis of 
BZD dependence 
(95% Cl)
40 51 
(31-50) (41-60)
63
(54-71)
69
(60-77)
82
{64-93)
97
(84-100)
a Data are expressed as rounded-up percentages of respondents.
the respective PY prevalences, which indicates that
there were some BZD users who had been depend-
(* i
ent in their lifetime, but who had not been depend­
ent during the past year, despite actual BZD use. 
To determine whether the differences in the
psychotropic drugs. Recent research in The 
Netherlands has shown that the 1-year prevalence 
of BZD use in the general population was 10.6% 
in 1992 (26). Combined with the high DSM-III-R 
and ICD-10 PY and LT prevalences of BZD depen-
prevalence of BZD dependence between the three dence in the out-patient BZD users described in 
groups were significant, the differences between the present study, this suggests that BZD depen-
pairs were tested by Chi-square analyses. The 
difference between the GP patients and the self- 
help patients was significant for all of the diag­
noses (/J<0.017). The difference between the GP
patients and the psychiatric out-patients was sig­
nificant (P<0.017) for all of the diagnoses except 
for the ICD-10 LT diagnosis (P=0.05). The differ­
ence between the psychiatric out-patients and the 
self-help patients was significant for the LT diag­
noses, but not for the PY diagnoses. On the whole, 
the difference in the prevalence of BZD depend­
ence between the GP patients and the self-help 
patients appears to be generalizable. However, 
differences in the prevalence of BZD dependence 
between the psychiatric out-patients and the other 
two groups should be interpreted with more cau­
tion.
dence is a major health problem. We do not expect 
that the substance dependence criteria of the 
recent DSM-IV will reflect a reduction in these 
prevalence figures, because the changes with 
regard to the former DSM-III-R have resulted in 
a closer resemblance to the ICD-10.
The three groups in this study were found to 
differ with respect to several sociodemographic 
characteristics, BZD dose, duration of BZD use 
and degree of psychopathology, The PY and LT 
prevalence of BZD dependence in the GP patients 
(according to DSM-III-R and ICD-10) differed 
significantly from the prevalence values in the self- 
help patients. The fact that the highest prevalence 
of BZD dependence was observed in the self-help 
patients was not surprising, as medication depen­
dence was the major issue of concern in the 
participating self-help groups. In addition,
Discussion higher degree of psychopathology (as reflected by
the SCL-90 total score) and the overrepresentation 
In many countries, BZDs are widely prescribed of female subjects, might be other related factors.
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Tablo 4. Past yuar (PY) and lifetime (LT) prevalence of positive ICD-10 drug dependence criteria and the diagnosis benzodiazepine (BZD) dependence”
Dependence criteria
Craving
Impaired ability to control BZD 
use once started, 
or to abstain from 
or reduce BZD use
Withdrawal symptoms or BZD 
use to relieve withdrawal 
symptoms
Tolerance
Salience oí BZD activities 
or time Involved in BZD-related 
activities
Persistence in use despite 
harmful effects
ICD-10 diagnosis 
of BZD dependence 
(95% Cl)
General practice 
patients 
(/?= 115)
PY
84
64
48
27
15
12
52
(42-61)
LT
85
71
56
41
26
17
63
(53-71)
8 Data are expressed as rounded-up percentages of respondents.
Psychiatric
out-patients
(n=124)
Self-help 
patients 
= 33)
PY LT PY LT
88 89 91 94
74 80 79 97
66 69 88 94
31 36 64 82
37 39 73 85
27 27 42 58
69 74 88 97
[60-77) (65-81) (72-97) (84-100)
Evidently caution is required when generalizing 
the results of this study. Undoubtedly there has 
been some selection bias due to the fact that the 
selection of BZD users was carried out over a 
period long enough to include all long-term BZD 
users, while due to varying prescription habits in 
the participating settings there has probably been 
variation in the selected numbers of short-term 
BZD users. Furthermore, BZD users living in 
towns in particular were selected, due to the non- 
rural nature of most of the participating settings 
and, although this was not apparent in any way, 
the compliance of the participating settings might 
have been related to a special interest in BZD 
dependence. As we have already mentioned, more 
women were selected in the relatively small self- 
help group sample, due to the restricted target 
membership of one of the two self-help groups. 
Finally, even if the nature of BZD dependence 
does not differ between countries, the prevalence 
figures in this study relate to the management of 
BZD use in The Netherlands, which will indeed 
be different in many other countries. However, in
representative of these types of settings in The 
Netherlands.
Compared to the earlier studies shown in Table 
1, in which the prevalence of BZD dependence 
ranged from 0.2 to 26% (12-20), our prevalence 
figures appear to be unexpectedly high. This could 
be due to several methodological differences. 
Unlike most of the earlier studies (13, 15-20), in 
which the prevalence of BZD dependence was 
assessed in patient samples consisting of BZD users 
and non-users, the present study was confined to 
BZD users, which obviously increased the preva­
lence figures. Furthermore, a lack of distinction 
between BZDs and other sedatives, anxiolytics and 
hypnotics (18-20), and between BZD dependence 
and abuse (15, 17), was avoided. However, we 
consider the conceptual changes that have been 
introduced in the DSM-III-R and ICD-10 in line 
with the substance dependence syndrome to be the 
most important methodological differences. Only 
one of the earlier studies (20) was also based on 
the DSM-III-R criteria. In most of the other studies 
the DSM-III and/or the ICD-9 criteria were used
view of the fairly good response rates of around (14—19). In contrast to the DSM-III, in which 
70% in all of the samples, the absence of signifi- tolerance and withdrawal were required for the 
cant sociodemographic differences between the diagnosis of dependence, the psycho-physiological-
participants and a substantial proportion of the 
non-participants, and the fact that this study was 
conducted in a number of different settings, we
social approach of the DSM-III-R has made it 
possible to diagnose BZD dependence even in the 
absence of tolerance and withdrawal, which increases
expect that the samples are at least reasonably the prevalence figures.
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A high prevalence implies that BZD users run a 
high risk of developing BZD dependence* This 
gives rise to the question of whether changes
ures is complicated and highly subjective. A struc­
tured instrument to diagnose BZD dependence, 
such as the SCAN, would be a direct and more
should be made in the management of BZDs in objective measure to facilitate the monitoring of 
clinical practice. Warnings about the liability of BZD users, but it would still be too time-consuming 
BZDs to cause dependence have been expressed for routine use in clinical practice, and it would 
before (27), but they could not be substantiated by 
prevalence figures based on generally accepted 
diagnostic criteria. This enabled other authors 
to state that the therapeutic benefits and safety 
of BZDs outweigh the small risk of dependence 
(28, 29). In an official task-force report by the
American Psychiatric Association, the liability of 
BZDs to cause dependence was still not considered 
to be a major problem (30), but the long-term use 
of BZDs was discouraged. The state of New York, 
by contrast, took the matter very seriously by 
deciding to add BZDs to its triplicate prescription
require interview training. Instead of a structured 
diagnostic interview, a reliable self-report question- 
naire could be developed for routine use in order 
to rate the severity of BZD dependence. Such an 
approach would be inore suitable for clinical prac­
tice, and could become an important asset in the 
clinical management of BZD use that aims to 
reduce non-indicated chronic BZD use.
programme, which obliges physicians to supply a 
copy of each BZD prescription to the dispensing 
pharmacist and the state Department of Health, 
and to adhere to some prescription-limiting rules 
(31). This continuing debate has raised sufficient References 
concern for guidelines to be put forward for the 
prescription of BZDs in order to limit the occur­
rence of BZD dependence and abuse as much 
as possible. The English Committee on Safety of 
Medicines (1988) recommended that BZDs should 
not be used for more than 4 consecutive weeks, and 
that the lowest possible dosage should not be 
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cription are valuable strategies that have been 
suggested by Sussman to minimize abuse and depen­
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hardly be expected to occur in (general) practice.
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